scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.BBRC.2009.06.053 |
P698 | PubMed publication ID | 19527684 |
P50 | author | Krzysztof Zablocki | Q61830426 |
Hanns Lochmüller | Q28321948 | ||
Dariusz C Górecki | Q58124683 | ||
Joanna Szczepanowska | Q60662489 | ||
P2093 | author name string | Krzysztof Zabłocki | |
Jan Fronk | |||
Katarzyna Wierzbicka | |||
Marta Onopiuk | |||
Sylwia Wojciechowska | |||
Wojciech Brutkowski | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | myoblast | Q1956694 |
P304 | page(s) | 463-466 | |
P577 | publication date | 2009-06-13 | |
P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
P1476 | title | Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts | |
P478 | volume | 386 |
Q43976956 | 3-Methylglutaconic aciduria--lessons from 50 genes and 977 patients. |
Q35853255 | A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. |
Q92932547 | Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy |
Q90414913 | CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors |
Q89851622 | Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function |
Q34776381 | Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. |
Q58781307 | Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in Mice and in Myogenic Cultures From DMD Patients |
Q40401861 | Dystrophin: The dead calm of a dogma |
Q38666009 | Enhanced Energetic State and Protection from Oxidative Stress in Human Myoblasts Overexpressing BMI1. |
Q51245941 | Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy. |
Q36964393 | Linking cytoarchitecture to metabolism: sarcolemma-associated plectin affects glucose uptake by destabilizing microtubule networks in mdx myofibers |
Q26772002 | Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy |
Q36351079 | Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model |
Q89531241 | Metabolic reprogramming of fibro/adipogenic progenitors facilitates muscle regeneration |
Q96954758 | Mitochondrial Function in Muscle Stem Cell Fates |
Q92515290 | Mitochondrial dysfunction causes Ca2+ overload and ECM degradation-mediated muscle damage in C. elegans |
Q35730485 | Mitofusin 2 Deficiency Affects Energy Metabolism and Mitochondrial Biogenesis in MEF Cells. |
Q36703351 | Nanotechnology inspired tools for mitochondrial dysfunction related diseases |
Q39499956 | P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment |
Q39323349 | Prospects for therapeutic mitochondrial transplantation |
Q43884201 | Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice. |
Q35201194 | Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle |
Q37998247 | Review: quantifying mitochondrial dysfunction in complex diseases of aging. |
Q24630041 | SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy |
Q90466803 | Social stress is lethal in the mdx model of Duchenne muscular dystrophy |
Q39330717 | Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy. |
Q90750443 | Transcriptome changes during the initiation and progression of Duchenne Muscular Dystrophy in C. elegans |
Search more.